See the Whole Landscape Shape What's Next in Pharma
GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
Products
GBI Health Data Intelligence Suite
Solutions
Full Life-Cycle Solutions for Pharmaceuticals
Powered by global drug pipeline data, the Competitive Landscape Analysis solution enables multidimensional analysis across drugs, targets, indications, and technologies. It helps R&D teams identify strategic opportunities, prioritize investments, and make more informed development decisions.
Drawing on data from six major global clinical trial registries, the Clinical R&D Insights solution provides deep visibility into global trial activity and protocol designs, helping teams optimize clinical development strategies and trial execution.
Drawing on data covering the National Reimbursement Drug List (NRDL), public procurement and tendering, Huiminbao (commercial health insurance), Patient Assistance Programs (PAPs), and healthcare policies and regulations, the Market Access Strategy solution supports market access planning, pricing analysis, and regional opportunity assessment to accelerate commercialization and market access.
Built on comprehensive researcher profiles, the GBI KOL/HCP Management solution enables researcher identification, segmentation, academic influence analysis, and collaboration network mapping, helping Medical Affairs, Marketing, and Sales teams improve researcher engagement and operational efficiency.
Industry News and Reports
Aggregating industry news and in-depth reports to help pharma companies stay ahead.
- NHC Issues New Measures to Strengthen Family Doctor Contracted Services
On August 25, 2026, China's National Health Commission (NHC), together with the National Administration of Traditional Chinese Medicine and the National Disease Control and Prevention Administration, issued the "Notice on Issuing Several Measures to Further Deepen the 'Six Expansions' and Strengthen the Implementation of Family Doctor Contracted Services" (the "Notice").
- WuXi XDC’s revenue up 41.5% to RMB 3.701b in 2026H1
On August 24, 2026, WuXi XDC (HKEX: 2268) released its interim results for the first half of 2026.
- Merck and AstraZeneca Lawsuits Against Medicare Price Negotiations Dismissed
On August 24, 2026, the U.S. Court of Appeals for the Third Circuit in Washington, D.C., ruled against Merck, rejecting its claim that Medicare drug price negotiations violate the First and Fifth Amendments.
- Mirxes reaches strategic partnership with GAIA Health in Philippines
On August 25, 2026, Mirxes (2629.HK) announced that its clinical diagnostic laboratory, M Diagnostics Philippines Inc., has officially signed a Strategic Memorandum of Understanding (MOU) with local Philippine wellness enterprise GAIA Health and Wellness Company.
- Hengrui Pharma submits NDA for HRG2010 in China
On August 24, 2026, Hengrui Pharma (600276.SH/1276.HK) announced that the National Medical Products Administration (NMPA) has accepted its National Drug Application (NDA) for HRG2010, intended for the treatment of Parkinson's disease. HRG2010 is a Class 2 innovative drug independently developed by Hengrui.
- Antengene’s ATG-201 receives clinical trial approval in Australia
On August 25, 2026, Antengene Corporation Limited (6996.HK) announced that the Phase I ATTRACT study of its proprietary compound ATG-201 has been approved by the Human Research Ethics Committee (HREC) in Australia, and the Clinical Trial Notification (CTN) scheme with the Therapeutic Goods Administration (TGA) has been completed.
In-Depth, Exclusive Industry Reports
Curated by expert analysts, offering in-depth analysis of emerging industry trends and the competitive landscape.
Scan the QR code to follow the GBIHealth WeChat Official Account for industry news, live webinars, thematic reports, and more.
Reliable partner for 95%+ key global medical industry players
Our clients are drawn from across pharma, medical device firms, CROs/CDMOs, investors, consulting firms, and others
See the Whole Landscape Shape What's Next in Pharma
GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
Contact Us